Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
October 2020 in “Проблемы эндокринологии” Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.
January 2013 in “Obstetrical & gynecological survey” Most women with hirsutism have normal hormone levels and can be treated with cosmetic methods; obesity and PCOS are common causes, and treatments depend on the underlying issue.
17 citations,
January 1995 in “The American Journal of Medicine” The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.
35 citations,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
17 citations,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
5 citations,
May 2018 in “Therapeutic advances in drug safety” Androgen use may increase the risk of stroke, but more research is needed.
6 citations,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
April 2008 in “Obstetrics, gynaecology and reproductive medicine” Hirsutism is often caused by high male hormone levels and can be treated with lifestyle changes and medications.
13 citations,
June 2018 in “Journal of Womens Health” Combination therapy with oral contraceptives and spironolactone improves hair growth, menstrual issues, and acne in women with PCOS.
71 citations,
September 2007 in “Cancer” Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
4 citations,
December 2019 in “Minerva Urology and Nephrology” 5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
18 citations,
July 2015 in “Drug Healthcare and Patient Safety” Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
20 citations,
September 2005 in “Endocrinology” Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.
January 2003 in “Humana Press eBooks” Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.
29 citations,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
6 citations,
July 2013 in “Acta Clinica Belgica” The document concludes that combination therapy is most effective for treating excessive hair growth in women with idiopathic hirsutism, and more research is needed to understand the condition.
195 citations,
May 2003 in “Obstetrics and gynecology (New York. 1953. Online)/Obstetrics and gynecology” Most women with excess hair growth have an underlying hormonal issue, often treated with medication and hair removal methods.
23 citations,
March 1994 in “Fertility and sterility” Most patients improved with oral contraceptives, but some needed additional treatment.
11 citations,
May 2003 in “Obstetrics and gynecology (New York. 1953. Online)/Obstetrics and gynecology” Hirsutism in women often indicates a hormonal imbalance and can be managed with a combination of hormonal treatments and hair removal methods.
4 citations,
April 2018 in “Journal of Mind and Medical Sciences” Patients should discuss risks with doctors before using finasteride for hair loss.
12 citations,
August 2020 in “Annals of Oncology” Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
9 citations,
September 2009 in “The Prostate” Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
228 citations,
February 2003 in “Urology” Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.
251 citations,
October 2014 in “The Journal of Clinical Endocrinology & Metabolism” The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.
99 citations,
August 2003 in “Fertility and Sterility” Too much male hormone is the main cause of Polycystic Ovary Syndrome.
82 citations,
May 2016 in “Best Practice & Research in Clinical Obstetrics & Gynaecology” The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.
50 citations,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.